Publications by authors named "Jan Snoeys"

Claim this Profile
A
Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of C-CD388 in the rat.
Aline Laenen, Shawn Flanagan, Grayson Hough, Jan Snoeys, Filip Cuyckens

Drug Metab Dispos· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human organotypic colon in vitro microtissue: unveiling a new window into colonic drug disposition.
Pedro G M Canhão, Jan Snoeys, Suzy Geerinckx, Marjolein van Heerden, An Van den Bergh

Eur J Pharm Sci· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioactivation of the β-Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Atabecestat Leads to Protein Adduct Formation on Glutathione S-Transferase Pi.
Megan Ford, Paul J Thomson, Adam Lister, Jan Snoeys, Laurent Leclercq

Chem Res Toxicol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward improved clearance predictions and distribution profiles employing the isolated perfused rat liver model: Experimental optimization.
Sofie Heylen, Johan Nicolaï, Stijn Van Asten, An Tuytelaars, Katie De Wagter, Jan Snoeys

Drug Metab Dispos· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP3A4-Mediated Bioactivation of the β-Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor JNJ-54861911 Results in Redox-Neutral Addition of Glutathione via Catalysis by Glutathione S-Transferase α1, Identified as the Major Target Protein in Human Hepatocytes.
Laurent Leclercq, Ronald de Vries, Valérie Koppen, Peter Verboven, Filip Cuyckens, Jan Snoeys

Chem Res Toxicol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective HLA Class II Allele-Restricted Activation of Atabecestat Metabolite-Specific Human T-Cells.
Megan Ford, Paul J Thomson, Jan Snoeys, Xiaoli Meng, Dean J Naisbitt

Chem Res Toxicol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment.
Rui Xu, Emmanuel Njumbe Ediage, Tom Verhaeghe, Jan Snoeys, Lieve Dillen

Nucleic Acid Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-release of paclitaxel and encequidar from amorphous solid dispersions increase oral paclitaxel bioavailability in rats.
Emilie Fynbo Petersen, Bjarke Strøm Larsen, Rasmus Blaaholm Nielsen, Ils Pijpers, Dries Versweyveld, Jan Snoeys

Int J Pharm· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease.
Shawn Pei Feng Tan, Marie-Emilie Willemin, Jan Snoeys, Hong Shen, Amin Rostami-Hodjegan

Clin Pharmacol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B.
Shinji Nakayama, Kota Toshimoto, Shinji Yamazaki, Jan Snoeys, Yuichi Sugiyama

CPT Pharmacometrics Syst Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules.
Stephanie Kourula, Merel Derksen, Ferran Jardi, Sophie Jonkers, Marjolein van Heerden, Jan Snoeys

Eur J Pharm Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat.
Qingqin S Li, Stephan Francke, Jan Snoeys, John Thipphawong, Gary Romano

BMC Genomics· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased bioavailability of a P-gp substrate: Co-release of etoposide and zosuquidar from amorphous solid dispersions.
Rasmus Blaaholm Nielsen, Bjarke Strøm Larsen, René Holm, Ils Pijpers, Jan Snoeys

Int J Pharm· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI/ML Models to Predict the Severity of Drug-Induced Liver Injury for Small Molecules.
Mohan Rao, Vahid Nassiri, Cristóbal Alhambra, Jan Snoeys, Freddy Van Goethem

Chem Res Toxicol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment.
Thomas N Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard-Azadian, Jan Snoeys

J Clin Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinational Inhibition of P-Glycoprotein-Mediated Etoposide Transport by Zosuquidar and Polysorbate 20.
Rasmus Blaaholm Nielsen, René Holm, Ils Pijpers, Jan Snoeys, Ulla Gro Nielsen

Pharmaceutics· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Joris Vandenbossche, Jeysen Yogaratnam, Vera Hillewaert, Freya Rasschaert, Willem Talloen, Jan Snoeys

Clin Pharmacol Drug Dev· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
Marie-Emilie Willemin, Peter Zannikos, Geert Mannens, Loeckie de Zwart, Jan Snoeys

Clin Pharmacokinet· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics.
Sara C Humphreys, John A Davis, Sajida Iqbal, Amin Kamel, Kenneth Kulmatycki, Jan Snoeys

Nucleic Acids Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Ed Gane, Man-Fung Yuen, Thomas N Kakuda, Tetsuro Ogawa, Yasushi Takahashi, Jan Snoeys

Antivir Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions.
Marie-Emilie Willemin, Thomas K Van Der Made, Ils Pijpers, Lieve Dillen, Annett Kunze, Jan Snoeys

Clin Pharmacokinet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and - correlation of P-glycoprotein inhibition.
Rasmus Blaaholm Nielsen, René Holm, Ils Pijpers, Jan Snoeys, Ulla Gro Nielsen

Int J Pharm X· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions.
Marie-Emilie Willemin, Thomas K Van Der Made, Ils Pijpers, Lieve Dillen, Annett Kunze, Jan Snoeys

Clin Pharmacokinet· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
Loeckie De Zwart, Jan Snoeys, Frank Jacobs, Lilian Y Li, Italo Poggesi

CPT Pharmacometrics Syst Pharmacol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel inhibitors of rat Mrp3.
Tom De Vocht, Christophe Buyck, Neel Deferm, Bing Qi, Pieter Van Brantegem, Jan Snoeys

Eur J Pharm Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis